Poland· PL-100494231

Macitentan Teva

A macitentan product containing macitentanum, registered in Poland by Teva Pharmaceuticals Polska Sp. z o.o.. The same ATC class is registered in 17 of our 19 countries.

ATC C02KX04

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedMacitentan TevaATCC02KX04REGISTER NO.PL-100494231PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Macitentan is registered in 17 of 19 countries.

Countries holding a registration under ATC C02KX04 (macitentan), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose

Macitentan · ATC C02KX04

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of macitentan costs, country by country.

Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Macitentan · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • IT Italy$161.10
  • CH Switzerland$108.22
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Macitentanum
Manufacturer
Teva Pharmaceuticals Polska Sp. z o.o.
Country
Poland (PL)
ATC code
C02KX04
ATC class
Macitentan
Defined daily dose
10 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991589608

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

83 interactions on record for macitentan.

Graded by severity as the source publishes them — 17 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Macitentan · interactions on record

83 records

  • 17 severe
  • 65 moderate
  • 1 minor

Most severe, free to view

  • KetoconazoleH02CA03severe
  • ErythromycinJ01FA01severe
  • ClarithromycinJ01FA09severe
  • KetoconazoleJ02AB02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Macitentan in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All macitentan products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Macepulan, Macicon
  • Belgium · Macitentan Ab, Macitentan Eg
  • Bulgaria · Мацитентан Зентива, Мацитентан Тева
  • Cyprus · Macitentan Sandoz
  • Czechia · Macitentan Olpha, Macitentan Teva
  • Germany · Macitentan 1 A Pharma, Macitentan Abdi
  • Denmark · Macitentan "sandoz", Macitentan Devatis
  • Estonia · Macitentan Norameda, Macitentan Olpha
  • Spain · Macitentan Dr. Reddys, Macitentán Glenmark
  • Finland · Macitentan Devatis, Macitentan Glenmark
  • France · Macitentan Olpha, Opsaren
  • United Kingdom (Northern Ireland) · Macitentan, Macitentan Accord Healthcare
  • Greece · Macitentan Bioars, Macitentan Pharmapath
  • Croatia · Jesoxade, Macitentan Teva
  • Hungary · Cidevia, Macepulan
  • Ireland · Macitentan Abdi, Macitentan Clonmel
  • Iceland · Macitentan Accord, Macitentan Accordpharma
  • Italy · Macitentan Abdi, Macitentan Aurobindo
  • Liechtenstein · Macitentan Accord, Macitentan Accordpharma
  • Lithuania · Macitentan Norameda, Macitentan Olpha
  • Luxembourg · Macitentan Ab, Macitentan Eg
  • Latvia · Macitentan Norameda, Macitentan Olpha
  • Malta · Cidevia, Macitentan Clonmel
  • Netherlands · Macitentan Aurobindo, Macitentan Cf
  • Norway · Macitentan Accord, Macitentan Accordpharma
  • Portugal · Macitentan Onkogen, Macitentano
  • Romania · Jesoxade, Macitentan Stada
  • Sweden · Macitentan Amarox, Macitentan Bioglan
  • Slovakia · Macitentan Olpha, Macitentan Stada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c8f64943-62b1-4b33-a3e9-a9e0963fb810
GET /v1/drugs/c8f64943-62b1-4b33-a3e9-a9e0963fb810?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "10 mg",
  "packaging": "05909991589608 ¦ Rpz ¦ 164920\n30 tabl.",
  "substance": "Macitentanum 10 mg",
  "common_name": "Macitentanum",
  "pl_product_id": "100494231",
  "pozwolenie_nr": "29408",
  "auth_procedure": "DCP",
  "authorisation_validity": "2030-12-01"
}

See everything about macitentan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.